Title : Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.

Pub. Date : 2019

PMID : 31165048






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
2 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
3 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens